Infantile leukemia

Authors

  • Pacharapan Surapolchai

Keywords:

-

Abstract

-

References

1. Silverman LB. Acute lymphoblastic leukemia in infancy. Pediatr Blood Cancer. 2007;49(7 Suppl):1070-3.
2. Noone AM, Howlader N, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2015, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2015/, based on November 2017 SEER data submission, posted to the SEER web site, April 2018.2
3. Wiangnon S, Veerakul G, Nuchprayoon I, Seksarn P, Hongeng S, Krutvecho T, SripaiboonkijN. Childhood cancer incidence and survival 2003-2005, Thailand: study from the Thai Pediatric Oncology Group. Asian Pac J Cancer Prev. 2011;12:2215-20.
4. Biondi A, Cimino G, Pieters R, Pui C-H. Biological andtherapeutic aspects of infant leukemia. Blood. 2000;96:24-33.
5. Hilden JM, Dinndorf PA, Meerbaum SO, Sather H, Villaluna D, HeeremaNA, et al. Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children’s Oncology Group. Blood. 2006;108:441-51.
6. Pieters R, Schrappe M, De Lorenzo P, Hann I, Rossi DG, Felice M, et al. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomized trial. Lancet. 2007;370:240-50.
7. Harrison CJ, Hills RK, Moorman AV, Grimwade DJ, Hann I, Webb DK, et al. Cytogenetics of childhood acute myeloid leukemia:United Kingdom Medical Research Council Treatment trials AML 10 and 12. J Clin Oncol. 2010;28:2674-81.
8. Winters AC, Bernt KM. MLL-rearranged leukemias -an update on science and clinical approaches. Front Pediatr. 2017;5:4.
9. Greaves MF, Maia AT, Wiemels JL, Forda AM. Leukemia in twins: lessons in natural history. Blood. 2003;102:2321-33.
10. Hernández AF, Menéndez P. Linking Pesticide Exposure with Pediatric Leukemia: Potential Underlying Mechanisms. Int J Mol Sci. 2016;17:461.
11. Vanhees K, de Bock L, Godschalk RW, van Schooten FJ, van Waalwijk van Doorn-Khosrovani SB. Prenatal exposure to flavonoids: implication for cancer risk. Toxicol Sci. 2011;120:59-67.
12. Michelle C, Turner MC, Donald T, Wigle DT, Krewski D. Residential Pesticides and Childhood Leukemia: A Systematic Review and Meta-Analysis. Environ Health Perspect. 2010;118:33-41.
13. Guest EM, Stam RW. Updates in the biology and therapy for infant acute lymphoblastic leukemia. Curr Opin Pediatr. 2017;29:20-6.
14. Masetti R, Vendemini F, Zama D, Biagi C, Pession A, Locatelli F. Acute Myeloid Leukemia in Infants: Biology and Treatment. Frontiers in Pediatrics. 2015;3:37.
15. Salzer WL, Jones TL, Devidas M, Hilden JM, Winick N, Hunger S, et al. Modifications to induction therapy decrease risk of early death in infants with acute lymphoblastic leukemia treated on Children’s Oncology Group P9407. Pediatr Blood Cancer. 2012;59:834-9.
16. Salzer WL, Jones TL, Devidas M, Dreyer ZE, Gore L, Winick NJ, et al. Decreased induction morbidity and mortality following modification to induction therapy in infants with acute lymphoblastic leukemia enrolled on AALL0631: a report from the Children’s Oncology Group. Pediatr Blood Cancer. 2015;62:414-8.
17. Tomizawa D, Koh K, Sato T, Kinukawa N, Morimoto A, Isoyama K, et al. Outcome of risk-based therapy for infant acute lymphoblastic leukemia with or without an MLL gene rearrangement, with emphasis on late effects: a final report of two consecutive studies, MLL96 and MLL98, of the Japan Infant Leukemia Study Group. Leukemia. 2007;21:2258-63.
18. Dreyer ZE, Hilden JM, Jones TL, Devidas M, Winick NJ, Willman CL, et al. Intensified chemotherapy without SCT in infant ALL: results from COG P9407 (Cohort 3). Pediatr Blood Cancer. 2015;62:419-26.
19. Mann G, Attarbaschi A, Schrappe M, De Lorenzo P, Peters C, Hann I, et al. Improved outcome with hematopoietic stem cell transplantation in a poor prognostic subgroup of infants with mixedlineage-
leukemia (MLL)-rearranged acute lymphoblastic leukemia: results from the Interfant-99 Study. Blood. 2010;116:2644-50.
20. Kosaka Y, Koh K, Kinukawa N, Wakazono Y, Isoyama K, Oda T, et al. Infant acute lymphoblastic leukemia with MLL gene rearrangements: outcome following intensive chemotherapy and hematopoietic stem cell transplantation. Blood. 2004;104:3527-34.
21. Kato M, Hasegawa D, Koh K, Kato K, Takita J, Inagaki J, et al. Allogeneic haematopoietic stem cell transplantation for infant acute lymphoblastic leukaemia with KMT2A (MLL) rearrangements: a retrospective study from the paediatric acute lymphoblastic leukaemia working group of the Japan Society for Haematopoietic Cell Transplantation. Br J Haematol. 2015;168:564-70.
22. Zwaan CM, Söderhäll S, Brethon B, Luciani M, Rizzari C, Sternberg D, et al. A phase 1/2, open-label, dose-escalation study of midostaurin in pediatric patients (Pts) with relapsed or refractory (R/R) acute leukemia: final results of study ITCC-024 (CPKC412A2114). Blood. 2015;126:2564.
23. Combination chemotherapy with or without lestaurtinib in treating younger patients with newly diagnosed acute lymphoblastic leukemia. Retrieved August 25, 2018, from https://clinicaltrials. gov/ct2/show/NCT00557193
24. Hematopoietic stem cell transplantation in the treatment of infant leukemia. Retrieved August 25, 2018, fromhttps://clinicaltrials.gov/ct2/show/NCT00357565?term=infant+ALL&cond=infant+leu
kemia&rank=1.
25. Total Therapy for infants with acute lymphoblastic leukemia (ALL) I. Retrieved August 25, 2018, from https://clinicaltrials.gov/ct2/show/NCT02553460?term=infant+ALL&cond=infant+leu
kemia&rank=5.
26. Bortezomib and vorinostat in younger patients with refractory or relapsed MLL rearranged hematologic malignancies. Retrieved August 25, 2018, from https://clinicaltrials.gov/ct2/show/NCT024
19755?term=infant+ALL&cond=infant+leukemia&rank=13.
27. Azacitidine and combination chemotherapy in treating infants with acute lymphoblastic leukemia and KMT2A Gene Rearrangement. Retrieved August 25, 2018, from https://clinicaltrials.gov/ct2/show/
NCT02828358?term=infant+ALL&cond=infant+leukemia&rank=12.
28. Chessells JM, Harrison CJ, Watson SL, Vora AJ, Richards SM.Treatment of infants with lymphoblastic leukaemia: results of the UK Infant Protocols 1987-1999. Br J Haematol. 2002;117:306-14.
29. Isoyama K, Eguchi M, Hibi S, Kinukawa N, Ohkawa H, Kawasaki H, et al. Risk-directed treatment of infant acute lymphoblastic leukaemia based on early assessment of MLL gene status: results of the Japan Infant Leukaemia Study (MLL96). Br J Haematol. 2002;118:999-1010.
30. Nagayama J, Tomizawa D, Koh K, Nagatoshi Y, Hotta N, Kishimoto T, et al. Infants with acute lymphoblastic leukemia and a germline MLL gene are highly curable with use of chemotherapy alone: results from the Japan Infant Leukemia Study Group. Blood. 2006;107:4663-5.
31. Sam TN, Kersey JH, Linabery AM, Johnson KJ, Heerema NA, Hilden JM, et al. MLL gene rearrangements in infant leukemia vary with age at diagnosis and selected demographic factors: a Children’s Oncology Group (COG) study. Pediatr Blood Cancer. 2012;58:836-9.
32. Masetti R, Vendemini F, Zama D, Biagi C, Pession A, Locatelli F. Acute myeloid leukemia in infants: biology and treatment. Front Pediatr. 2015;3:37.

Downloads

Published

2018-12-25

Issue

Section

บทความฟื้นวิชา (Literature review)